199 related articles for article (PubMed ID: 21362113)
1. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
3. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
[TBL] [Abstract][Full Text] [Related]
5. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
Brophy DF; Martin EJ; Barrett JC; Nolte ME; Kuhn JG; Hedner U; Ezban M
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082
[TBL] [Abstract][Full Text] [Related]
6. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
[TBL] [Abstract][Full Text] [Related]
8. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
10. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
11. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U
Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065
[TBL] [Abstract][Full Text] [Related]
13. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
[TBL] [Abstract][Full Text] [Related]
14. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.
Schut AM; Hyseni A; Adelmeijer J; Meijers JC; De Groot PG; Lisman T
Thromb Haemost; 2014 Aug; 112(2):304-10. PubMed ID: 24695949
[TBL] [Abstract][Full Text] [Related]
15. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
Othman M; Powell S; Hopman WM; Lillicrap D
Haemophilia; 2010 Nov; 16(6):919-25. PubMed ID: 20609015
[TBL] [Abstract][Full Text] [Related]
16. First 20 years with recombinant FVIIa (NovoSeven).
Hedner U; Lee CA
Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
18. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
Sørensen B; Ingerslev J
J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
20. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
